Literature DB >> 17331841

The effect of immunosuppressive drug rapamycin on regulatory CD4+CD25+Foxp3+T cells in mice.

Yanyan Qu1, Baojun Zhang, Liang Zhao, Guangwei Liu, Haixia Ma, Enyu Rao, Chun Zeng, Yong Zhao.   

Abstract

CD4(+)CD25(+)Regulatory T (Treg) cells are crucial for negatively regulating immune responses. Rapamycin (rapa) is an immunosuppressive agent which is widely used for preventing acute graft rejection in patients and has been used to induce operational tolerance in mouse models. The aim of the present study was to determine the effect of rapa on CD4(+)CD25(+)Foxp3(+)Treg cells in a mouse model. After C57BL/6 mice were intraperitoneally given 1.5 mg/kg/day of rapa for 14 days, the percentages, cell numbers, phenotype and function of CD4(+)CD25(+)Treg cells were determined by flow cytometry as well as the in vitro and in vivo functional assays. The cell numbers of CD4(+) and CD4(+)CD25(+)Treg cell subsets were markedly decreased in rapa-treated mice as reported. However, rapa significantly enhanced the ratios of CD4(+)CD25(+)Treg cells or CD4(+)CD25(+)Foxp3(+)Treg cells to CD4(+)T cells in spleens and thymi of mice (P<0.01) respectively. Furthermore, splenic CD4(+)CD25(+)Treg cells in rapa-treated mice showed immunosuppressive ability on the immune response of T effector cells to alloantigens or mitogen as efficiently as the control CD4(+)CD25(+)Treg cells in vitro and in vivo. Thus, rapa could significantly enhance the percentages of CD4(+)CD25(+)Foxp3(+)Treg cells in the thymus and the periphery while keeping these cells functional, indicating that CD4(+)CD25(+)Treg cells are more resistant to rapa than other CD4(+)T cells. The different effects of rapa on CD4(+)CD25(+)Treg and T effector cells make rapa to be a favorable choice for inducing immune tolerance to self-, allo-, or xeno-antigens.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17331841     DOI: 10.1016/j.trim.2007.01.002

Source DB:  PubMed          Journal:  Transpl Immunol        ISSN: 0966-3274            Impact factor:   1.708


  47 in total

1.  Regulatory T cells require mammalian target of rapamycin signaling to maintain both homeostasis and alloantigen-driven proliferation in lymphocyte-replete mice.

Authors:  Ying Wang; Geoffrey Camirand; Yan Lin; Monica Froicu; Songyan Deng; Warren D Shlomchik; Fadi G Lakkis; David M Rothstein
Journal:  J Immunol       Date:  2011-01-26       Impact factor: 5.422

2.  High frequency of central memory regulatory T cells allows detection of liver recipients at risk of early acute rejection within the first month after transplantation.

Authors:  Francisco Boix-Giner; Olga Millan; David San Segundo; Pedro Muñoz-Cacho; Esther Mancebo; Santiago Llorente; Lourdes Rafael-Valdivia; Antoni Rimola; Emilio Fábrega; Anna Mrowiec; Luis Allende; Alfredo Minguela; Jose M Bolarín; Estela Paz-Artal; Marcos López-Hoyos; Mercé Brunet; Manuel Muro
Journal:  Int Immunol       Date:  2015-08-12       Impact factor: 4.823

Review 3.  Foxp3+ regulatory T cells: differentiation, specification, subphenotypes.

Authors:  Markus Feuerer; Jonathan A Hill; Diane Mathis; Christophe Benoist
Journal:  Nat Immunol       Date:  2009-07       Impact factor: 25.606

Review 4.  The effects of immunosuppression on regulatory CD4(+)CD25(+) T cells: impact on immunosuppression selection in transplantation.

Authors:  Aqeel Javeed; Yong Zhao
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

5.  Increased Foxp3+Helios+ Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells.

Authors:  Yi-Bin Chen; Yvonne A Efebera; Laura Johnston; Edward D Ball; David Avigan; Lazaros J Lekakis; Carlos R Bachier; Paul Martin; Omar Duramad; Yasuyuki Ishii; Semi Han; Yu-Jin Jung; Dana Lee; Lori Kunkel; Robert S Negrin; Jack D Bui
Journal:  Biol Blood Marrow Transplant       Date:  2017-01-16       Impact factor: 5.742

Review 6.  Histone deacetylase inhibitors and transplantation.

Authors:  Ran Tao; Edwin F de Zoeten; Engin Ozkaynak; Liqing Wang; Bin Li; Mark I Greene; Andrew D Wells; Wayne W Hancock
Journal:  Curr Opin Immunol       Date:  2007-08-24       Impact factor: 7.486

Review 7.  mTOR: taking cues from the immune microenvironment.

Authors:  Greg M Delgoffe; Jonathan D Powell
Journal:  Immunology       Date:  2009-08       Impact factor: 7.397

Review 8.  Role of the PD-1 pathway in the immune response.

Authors:  L V Riella; A M Paterson; A H Sharpe; A Chandraker
Journal:  Am J Transplant       Date:  2012-08-17       Impact factor: 8.086

Review 9.  Combination of intensive chemotherapy and anticancer vaccines in the treatment of human malignancies: the hematological experience.

Authors:  Knut Liseth; Elisabeth Ersvaer; Tor Hervig; Øystein Bruserud
Journal:  J Biomed Biotechnol       Date:  2010-06-02

10.  PD-L1 regulates the development, maintenance, and function of induced regulatory T cells.

Authors:  Loise M Francisco; Victor H Salinas; Keturah E Brown; Vijay K Vanguri; Gordon J Freeman; Vijay K Kuchroo; Arlene H Sharpe
Journal:  J Exp Med       Date:  2009-12-14       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.